Agenus logo
Agenus AGEN
$ 6.63 0.45%
report update icon

Quarterly report 2026-Q1
added 05-11-2026

Agenus Income Statement 2025-2008 | AGEN

Brief overview of financial results at Agenus

The overview follows changes across a five-year period. Agenus reported revenue of $88.2 million in 2020 and $114 million by 2025. Across the full period, sales moved by +29.5%; the average annual rate was 5.3%. This represents moderate business growth.

Gross profit changed from $85.8 million to $113 million (+31.9%). Direct costs grew more slowly than revenue and improved the economics of sales. Comparing the endpoints gives gross margins of 97.3% and 99.1%. The relationship between gross profit and revenue changed only slightly.

EBITDA changed from −$110 million to −$10.2 million (+90.8%). Additional revenue translated efficiently into EBITDA. EBITDA margin was −124.8% at the start and −8.9% at the end. The increased EBITDA share is a positive sign.

The net financial result changed from −$183 million to −$3.1 million. The negative result improved without reaching break-even.

The five-year change in capitalization reached +15310%: from $635 thousand to $97.8 million. Valuation expanded much faster than the underlying results.

What the figures show

The results present an uneven picture without one dominant signal. Key strengths include improving gross profitability, a stronger final result and sales growth. The weaker side of the profile includes a narrow EBITDA buffer. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Agenus

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

97.8 M 70.6 M 10.7 M 25.8 M 632 K 635 K 513 M 385 M 359 M 321 M 246 M 301 M 93.8 M 103 M 55.9 M - - -

Shares

29.7 M 21.5 M 17.9 M 14.1 M 229 K 173 K 135 M 111 M 98.4 M 87.1 M 78.2 M 59.8 M 29.8 M 23.6 M 19.9 M - - -

Historical Prices

3.29 3.29 0.6 1.83 2.76 3.68 3.74 3.37 3.61 4 3.15 5.03 3.09 4.55 2.78 117 105 270

Net Income

-3.08 M -232 M -257 M -231 M -28.7 M -183 M -108 M -160 M -121 M -127 M -87.9 M -42.5 M -30.1 M -11.3 M -23.3 M -21.9 M -30.3 M -

Revenue

114 M 103 M 156 M 98 M 296 M 88.2 M 150 M 36.8 M 42.9 M 22.6 M 24.8 M 6.98 M 3.05 M 16 M 2.76 M 3.36 M 3.33 M -

Cost of Revenue

1.02 M 486 K 3.11 M 10.6 M 3.47 M 2.35 M - - - - - - - - - - - -

Gross Profit

- - - - - - -18.3 M -87.8 M -73.2 M -72.4 M -45.6 M -15.4 M -10.5 M 4.72 M 2.76 M - - -

Operating Income

-20.2 M -120 M -160 M -179 M 25.7 M -117 M -70.1 M -124 M -104 M -107 M -80.7 M -43.3 M -25 M -6.74 M -19.1 M -21.8 M -27.7 M -

Interest Expense

72.4 M 5.83 M 37 K 10.6 M - - - - - - - 1.26 M 2.43 M 4.72 M 4.21 M 4.87 M 5.34 M -

EBITDA

-10.2 M -107 M -146 M -172 M 32.5 M -110 M -57.7 M -119 M -101 M -101 M -59.8 M -35 M -24.4 M -5.12 M -16.8 M -18.3 M -23.6 M -

Operating Expenses

- - - - - - 46 M 37.3 M 33.7 M 33.1 M 28.4 M 21.2 M 14.5 M 11.5 M 21.8 M - - -

General and Administrative Expenses

54.4 M 71.9 M 78.7 M 81 M 76.4 M 59.2 M 46 M 37.3 M 33.7 M 33.1 M 28.4 M 21.2 M 14.5 M 11.5 M 10.8 M 12.1 M 14.1 M -

All numbers in USD currency

Quarterly Income Statement Agenus

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

37.9 M 31.9 M 28.1 M 24.5 M 23.6 M 21.6 M 21.1 M 20.4 M 19.7 M 18.9 M 17.6 M 15.9 M - 287 K 277 K 258 K - 235 K 223 K 200 K - 183 K 169 M 145 K - 138 M 135 M 130 K - 115 M 105 M 103 K - 99.9 M 99.2 M 93.5 M - 87.2 M 87 M 86.7 M - 84.6 M 76.4 M 66.7 M - 62.8 M - - - - - 25.1 M - - - 22.3 M - - - 18.8 M

Net Income

39.2 M 63.9 M -30 M -26.4 M - -67.2 M -54.8 M -63.5 M - -64.5 M -73.4 M -70.9 M - -56.7 M -49.2 M -50.6 M - 177 M -84 M -54.4 M -37.7 M -51.6 M -48.2 M -45.3 M -30.9 M -46.3 M -51.9 M 17.4 M -48.8 M -33.7 M -25.2 M -54.3 M -35 M -36.8 M -31.7 M -17.1 M -26.1 M -40.8 M -28.3 M -31.8 M -15.6 M -13.1 M -40.4 M -18.7 M -26 M -8.11 M -8.04 M -357 K -5.78 M -7.32 M -11.1 M -5.84 M -5.44 M -5.73 M -6.92 M 6.77 M -6.02 M -5.53 M -5.76 M -5.96 M

Revenue

33.7 M 30.2 M 25.7 M 24.1 M - 25.1 M 23.5 M 28 M - 24.3 M 25.3 M 22.9 M - 22.8 M 20.9 M 25.9 M - 253 M 10.7 M 11.7 M 31.3 M 14.8 M 26.9 M 15.1 M 34.5 M 19.9 M 15.7 M 79.9 M 6.45 M 12.8 M 15.9 M 1.64 M 8.35 M 3.36 M 4.21 M 27 M 5.58 M 4.45 M 6.59 M 5.96 M 7.64 M 6.85 M 6.38 M 3.95 M 1.62 M 1.56 M 3.07 M 721 K 393 K 736 K 807 K 1.11 M 1.09 M 869 K 627 K 13.4 M 644 K 654 K 786 K 672 K

Cost of Revenue

- 642 K 243 K 137 K - 146 K 115 K 107 K - 303 K 254 K 2.29 M - 308 K 2.02 M 543 K - 817 K 667 K 1.1 M - 911 K 634 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

15.1 M -4.54 M -16.7 M -13.3 M - -31.5 M -30.2 M -32.9 M - -46.3 M -54.7 M -54.3 M - -41.6 M -44.6 M -35.5 M - 188 M -66.4 M -41.4 M - -34.8 M -33.3 M -27.5 M - -35.9 M -41.1 M 26.2 M - -26.1 M -16.6 M -41.7 M - -31.7 M -28.9 M -13.3 M - -36.2 M -23.6 M -28 M - -11.1 M -33.2 M -18.3 M - -7.67 M -8.5 M -9.82 M - -6.81 M -7.33 M -4.61 M - -4.54 M -5.77 M 7.8 M - -4.44 M -4.7 M -5.02 M

Interest Expense

38.8 M 81.6 M -12 K -264 K - 19 K 7.14 M -1.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 566 K 397 K - 310 K 296 K 356 K - 347 K 491 K 1.23 M - -1.19 M -1.15 M -1.14 M - 1.09 M 1.05 M 948 K

EBITDA

15.6 M - - -10.1 M - - - -29.5 M - - - -51.8 M - -36.6 M -41.2 M -33.8 M - 193 M -62.9 M -39.6 M - -29.4 M -29.8 M -25.8 M - -30.9 M -37.8 M 27.8 M - -21.3 M -13.5 M -40.2 M - -27.1 M -25.8 M -11.7 M - -32.6 M -21.1 M -26.7 M - -9.66 M -32.3 M -17.8 M - -6.65 M -7.91 M -9.56 M - -6.37 M -7.02 M -4.46 M - -3.05 M -4.68 M 8.35 M - -2.74 M -3.57 M -4.46 M

General and Administrative Expenses

6.86 M 10.9 M 15.5 M 15.7 M - 17.3 M 16.8 M 16.9 M - 18.9 M 20.4 M 18.2 M - 18.1 M 18.9 M 19 M - 21.4 M 16.6 M 16.4 M - 14.4 M 14.2 M 10.6 M - 11.5 M 11.4 M 10.8 M - 9.2 M 9.48 M 8.93 M - 8.05 M 8.14 M 7.77 M - 8.11 M 7.12 M 9.23 M - 6.41 M 8.02 M 5.49 M - 4.92 M 6.13 M 5.16 M - 3.58 M 4.64 M 2.89 M - -2.59 M -3.36 M -2.87 M - 2.57 M 2.66 M 2.88 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Agenus (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 107.57 -4.15 % $ 5.4 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
MediciNova MediciNova
MNOV
$ 1.29 -3.01 % $ 63.3 M usaUSA
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 8.36 -1.07 % $ 1.57 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
uniQure N.V. uniQure N.V.
QURE
$ 40.07 9.3 % $ 2.3 B niderlandNiderland
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Alkermes plc Alkermes plc
ALKS
$ 48.34 -4.28 % $ 7.96 B irlandaIrlanda
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.18 -0.08 % $ 269 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA